Topiramate induced metabolic acidosis and kidney stones – a case study by Tomas Salek et al.
Special issue: Responsible writing in science
©Copyright by Croatian Society of Medical Biochemistry and Laboratory Medicine. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creative-
commons.org/licenses/by/4.0/) which permits users to read, download, copy, distribute, print, search, or link to the full texts of these articles in any medium or format and to remix, transform and build upon 
the material, provided the original work is properly cited and any changes properly indicated .
Biochemia Medica 2017;27(2):404–10  http://doi.org/10.11613/BM.2017.042 
404
Abstract
Introduction: The aim of this study is to present a case of 44 years old woman with topiramate induced metabolic acidosis and kidney stones.
Materials and methods: The laboratory features of topiramate caused renal tubular acidosis in blood and urine during topiramate treatment, 
with correction of metabolic acidosis by potassium citrate, and after topiramate withdrawal are presented. Differential diagnosis of all possible cau-
ses of metabolic acidosis is discussed.
Results: The results revealed negative base excess in extracellular fluid of - 9.2 mmol/L, low serum HCO3- concentration (18.6 mmol/L), trend to al-
kaline urine (pH 6.39) and low urine citrate concentration (0.3 mmol/24h). After topiramate withdrawal, all parameters of the internal environment 
normalized.
Conclusions: This study has shown that long-term topiramate administration could induce metabolic acidosis and consequently urholithiasis. Thus, 
we could recommend testing blood acid base balance, urinary pH and citrates in patients taking topiramate and suffering from kidney stones. 
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Kidney stones affect approximately 10% of the Eu-
ropean population. It means that medical doctors 
frequently encounter this disease.  It is a metabolic 
disease with urological complications. Kidney 
stone analysis and identification of risk factors for 
kidney stone formation are the first steps in the di-
agnostic procedure in patients with urolithiasis. 
Risk factors for kidney stone formation include 
family history of kidney stones, low fluid intake, 
some types of diets, certain pharmacotherapy, 
some diseases, increased concentration of stone 
forming substances and decreased concentration 
of inhibitors of stone formation. Laboratory medi-
cine plays key role in identification of risk factors. 
European guidelines on urolithiasis recommend 
many laboratory blood and urine tests for meta-
bolic evaluation of patients with kidney stones of 
known and unknown composition. Clear algo-
rithms with treatment decision points are defined 
for each type of kidney stones for prevention of 
kidney stone recurrence (1).
The acid base balance plays a very important role 
mainly in calcium phosphate, uric acid and cystine 
stone formation. The phosphoric acid system is 
one of the most important urinary buffers. At the 
pH level above the second acid dissociation con-
stant of phosphoric acid (> 6.8) the monohydro-
gen phosphate (HPO42-) predominates in urine 
and is able to accept calcium ions. It increases the 
probability of crystals and stones formation. The 
systemic metabolic acidosis causes hypercalciuria 
and hypocitraturia, which also contribute to calci-
um nephrolithiasis formation.
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Some drugs may also contribute to kidney stones 
formation. They may crystallize in urine or disturb 
urine composition. More than 20 drugs which con-
tribute to kidney stone formation are listed in Eu-
ropean guidelines (1).
Topiramate is an antiepileptic drug which leads to 
mixed renal tubular acidosis by the inhibition of 
carbonic anhydrase in renal tubules, which leads 
to systemic metabolic acidosis with low plasma bi-
carbonate concentration and alkaline urine pH 
with low urine citrate concentration. These meta-
bolic changes result in calcium phosphate stone 
formation (2).
The aim of this study is to present a case of a 44 
years old woman with topiramate induced meta-
bolic acidosis and kidney stones. 
Material and methods
A 44-year old woman, nonsmoker, presents at 
urology clinic for right low back pain in April 2012. 
She did not have signs of renal colic or fever. Her 
previous medical history included only chronic 
bronchitis and migraine headaches for years. Since 
2007 she was taking topiramate at the daily dose 
of 200 mg for migraine headache prophylaxis, 
which greatly improved her headaches. She was 
also taking sumatriptan in the dose of 50 mg dur-
ing migraine attack. It was prescribed by pain spe-
cialist.
Her body mass index (BMI) was 25.6 kg/m2. It indi-
cates the range of overweight. Other physical ex-
amination did not find any abnormality.
After careful physician examination by urologist in 
April 2012, plane X-ray of the patient‘s abdomen 
was performed, following by computer tomogra-
phy. She visited urologist regularly every 6 months.
In May 2012, on admission to metabolic clinic arte-
rial blood gas analysis was performed. At the same 
time blood sample and spot urine sample were 
obtained in fasting state at 7:00 am. Three weeks 
later a 24-hour urine sample was obtained. The 
24-hour urine specimen was collected in a con-
tainer with 15 mL of 6 molar HCl.
In November 2012 morning fasting venous blood 
sample and spot urine sample was obtained. Fast-
ing venous blood sample and spot urine sample at 
metabolic clinic were obtained every six months.
VACUETTE® red top 6 mL tubes (Greiner Bio-One 
GmbH, Kremsmünster, Austria) with clot activator 
and without gel separator were used for venous 
blood collection. The separation of cells from se-
rum was performed within 1 hour. Transport on 
ice was used for parathormone testing. Capilaries 
with balanced heparin (Radiometer, Brønshøj, 
Denmark) were used for arterial blood gas analy-
sis. Transportation of samples was on ice and sam-
ples were analyzed within 15 minutes.
Whole blood pH, whole blood pCO2, whole blood 
pO2 were performed on Radiometer ABL 800 FLEX 
blood gas analyzer (Radiometer, Brønshøj, Den-
mark) by electrochemistry methods. Serum glu-
cose, electrolytes, urea, enzymatic creatinine stan-
dardized to NIST SRM 967 reference material, uric 
acid, total bilirubin, alanine aminotransferase, as-
partate aminotransferase, gamma-glutamyl trans-
ferase, alkaline phosphatase, total cholesterol, tria-
cylglycerols, total protein, albumin, C-reactive pro-
tein, serum HCO3- (enzymatic test), cystatin C 
traceable to reference material DA ERM 472, para-
thyroid hormone, urine citrate were measured on 
ci16200 Abbott Architect analyzer (Abbott Labora-
tories, Illinois, USA).
Estimation of glomerular filtration rate was calcu-
lated by Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation from serum cre-
atinine. pH in urine was measured on pH meter 
PerpHecT Meter 330 (Thermo Scientific, Beverly, 
USA).
Oxalate in urine is measured on Analytik Jena AG 
Specord 40 analyzer (Analytik Jena, Jena, Germa-
ny). Oxalate is precipitated with calcium sulfate 
and ethanol, re-dissolved and then oxidized by ox-
alate oxidase. Reagents are from Instruchemie (In-
struchemie, Delfzijl, The Netherlands). Urinary sed-
iment was performed on Arkray analyzer IRIS IQ 
200 (Arkray, Kyoto, Japan). Urinary cystin and diba-
sic aminoacids were mearured on amino acid ana-
lyzer AAA 400 (Ingos, Prague, Czech Republic) by 
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medium pressure liquid ionex chromatography 
with postcolumn ninhydrin derivatization and de-
tection at 440 and 570 nm. Polarized light micros-
copy was used for determination of stone compo-
sition.
The patient signed informed consent regarding 
publication of this article and the case study was 
approved for publication by the Tomas Bata hospi-
tal ethics committee.
Results
In April 2012, plane X-ray of the abdomen showed 
presence of the kidney stones. Urolithiasis was 
confirmed in medium right calyx and inferior left 
calyx (both in diameter of 3 mm) by computed to-
mography. The composition of the stone was un-
known, but the stone was X-ray contrastive. We 
thought it could be a calcium phosphate stone.
On admission (May 2012), during only topiramate 
treatment, results of patient arterial blood gas 
analysis revealed metabolic acidosis (negative 
base excess of – 9.2 mmol/L was calculated from 
pH and pCO2), serum bicarbonate concentration 
by enzymatic test was 18.6 mmol/L), urine analysis 
showed trend to alkaline urine (pH 6.39) and low 
urine citrate concentration (0.3 mmol/24h) and all 
other parameters were normal. Results are pre-
sented in Table 1. According to results topiramate 
induced urolithiasis was suspected and patient 
was advised to discontinue topiramate treatment, 
but she did not want to as it improves her head-
aches.
In order to correct metabolic acidosis, since June 
2012 potassium citrate was administred to patient. 
Following therapy, HCO3- concentration was par-
tially corrected to 21 mmol/L. Results are present-
ed in Table 2.
Table 1. Results of basic biochemistry analysis, arterial blood gas analysis and urine analysis in patient on admission in May 2012, dur-
ing topiramate treatment only.
Test Unit Result Reference range
Basic biochemistry analysis (9th May 2012)
Serum glucose mmol/L 6.5 3.9–5.5
Serum sodium mmol/L 139 136–144
Serum potassium mmol/L 4.4 3.8–5.1
Serum chloride mmol/L 111 95–107
Serum urea mmol/L 4.1 2.0–6.7
Serum creatinine µmol/L 71 49–90
eGFR (CKD-EPI equation) mL/min/1.73m2 90 90–150
Serum uric acid µmol/L 219 140–340
Serum total bilirubin µmol/L 6 < 17
Serum ALT U/L 37 °C 30.6 < 43.8
Serum AST U/L 37 °C 16.2 < 40.2
Serum GGT U/L 37 °C 24.6 < 106.2
Serum AP U/L 37 °C 51.6 < 150
Serum cholesterol mmol/L 6.45 < 5
Serum triacylglycerides mmol/L 1.71 < 1.7
Serum total protein g/L 69.4 64.0 – 83.0
Serum albumin g/L 43.9 35.0 – 52.0
Serum C-reactive protein mg/L < 1 < 3
Serum HCO3- mmol/L 18.6 22.0 – 28.0
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Test Unit Result Reference range
Serum calcium mmol/L 2.25 2.10 – 2.55
Serum parathyroid hormone pmol/L 3.6 1.6 – 7.2
Serum cystatin C mg/L 0.93 0.40 – 0.96
Arterial Blood gas analysis  (9th May 2012)
Whole blood pH pH units 7.386 7.36 – 7.44
Whole blood pCO2 kPa 3.61 4.6 – 6.0
Whole blood pO2 kPa 11.75 10.67 – 14.40
Actual HCO3- (calculated) mmol/L 15.9 22.0 – 28.0
Base excess (calculated) mmol/L - 9.2 - 2.5 – 2.5
Saturation of hemoglobin (measured) % 96.8 95.0–99.0
Spot urine analysis (9th May 2012)
Urine pH pH units 6.39
Urine calcium/creatinine mol/mol 0.38 < 0.60
Urine uric acid/creatinine mol/mol 0.18 < 0.30
Urine magnesium/creatinine mol/mol 0.27 0.2-0.5
Urine oxalate/creatinine mol/mol 0.011 < 0.04
Urine citrate/creatinine mol/mol 0.03 > 0.15
Urine sediment (9th May 2012)
Erythrocytes in urine sediment x 106 /L 9 <  10
Leukocytes in urine sediment x 106 /L 13 <  15
Biochemistry analysis of 24h urine (31th May 2012)
Urine volume/24h L 2.95 1.5 – 3.0
Sodium/24h mmol/24h 145 100 – 260
Potassium/24h mmol/24h 71 35 – 80
Calcium/24h mmol/24h 6.8 2.5 – 7.5
Inorganic phosphate/24h mmol/24h 27 13 – 35
Magnesium/24h mmol/24h 3.4 3 – 5
Oxalate/24h mmol/24h 0.325 0 – 0.5
Citrate/24h mmol/24h 0.3 2.5 – 5.0
eGFR - estimated glomerular filtration rate; CKD-EPI - Chronic Kidney Disease – Epidemiology Collaboration; ALT - alanine 
aminotransferase; AST - aspartate aminotransferase; GGT - gamma-glutamyl transferase; AP - alkaline phosphatase.
Table 1. continued
From May 2013 to July 2014 repeated spot urine 
samples yielded citrate to creatinine ratio 0.04, 
0.04, 0.05 and 0.05 (reference range is over 0.15 
mol/mol). Spot urine pH ranged from 6.54 to 7.52.
In December 2014, a regular urologic visit ultraso-
nography revealed that her stones enlarged. Fol-
lowing these results she stopped taking both topi-
ramate and potassium citrate. After this withdraw-
al serum bicarbonate concentration and urine ci-
trates normalized. Results are presented in Table 3.
The extracorporeal shock wave lithotripsy was 
performed on right kidney three times. Urography 
showed that the patient’s calyx neck was narrow 
but the last lithotripsy, in January 2016, was suc-
cessful. The stone was composed of calcium phos-
phate (80%) and calcium oxalate (20%). It consist-
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Test Unit Results Reference range
Basic biochemistry analysis (14th November 2012)
Serum sodium mmol/L 138 136 - 144
Serum potassium mmol/L 4.2 3.8 – 5.1
Serum chloride mmol/L 110 95 - 107
Serum HCO3- mmol/L 21 22.0 – 28.0
Spot urine analysis (14th November 2012)
Urine pH pH units 6.79
Urine calcium/creatinine mol/mol 0.44 < 0.60
Urine citrate/creatinine mol/mol 0.04 > 0.15
Table 2. Results of basic biochemistry analysis and urine analysis in patient in November 2012, during topiramate and potassium 
citrate treatment
Test Unit Results Reference range
Basic biochemistry analysis (10th December 2014)
Serum HCO3- mmol/l 27 22.0 – 28.0
Spot urine analysis (15th December 2014)
Urine pH pH units 6.28
Urine calcium/creatinine mol/mol 0.28 < 0.60
Urine uric acid/creatinine mol/mol 0.28 < 0.30
Urine inorganic phosphate/creatinine mol/mol 1.72 < 2.8
Urine magnesium/creatinine mol/mol 0.3 0.2 - 0.5
Urine oxalate/creatinine mol/mol 0.004 < 0.04
Urine citrate/creatinine mol/mol 0.21 > 0.15
Table 3. Results of basic biochemistry analysis and urine analysis in patient in December 2014, after both topiramate and potassium 
citrate withdrawal
ed of Brushite (60%), Apatite (20%), and Whedelit 
(20%) according to mineralogical terminology.
Discussion
In the present study we presented a case of the 
woman with topiramate induced urolithiasis.
Discontinuation of topiramate and normalization 
of acid base status in our patient confirmed the 
cause of metabolic acidosis and probably its con-
tribution to kidney stone formation. It was previ-
ously described that topiramate can induce sys-
temic metabolic acidosis by multiple mechanisms 
and lead to calcium phosphate kidney stones, 
which is consistent with stone composition of our 
patient. This drug induces renal tubular acidosis. It 
is combined proximal and distal tubular disorder 
(3). Low urine citrate excretion, urine pH over 6 
and increased urine HCO3- ion are typical urine 
profile of topiramate treatment (4). 
Her overweight might also have contributed to 
stone formation, because it is the risk factor for 
kidney stones formation. It was demonstrated in a 
study by Shavit et al., that overweight kidney 
stones formers show clear alterations in metabolic 
urinary profiles that are associated with increased 
overall risk of stone formation. This greater risk is 
primarily due to raised urinary uric acid and sodi-
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um, lower urine pH and higher prevalence of hy-
percalciuria (5). 
Normalization of metabolic acidosis due to topira-
mate treatment after its withdrawal was reported 
in a case study of a 75 year old male (6). It is consis-
tent with our results.
Some cases of metabolic acidosis due to topira-
mate treatment may be severe with highly nega-
tive base excess of – 14.1 mmol/L (7). We have ob-
served lower degree of metabolic acidosis.
The study by Maalouf et al. showed that the preva-
lence of symptomatic nephrolithiasis among long-
term topiramate users was 10.7% (8). According to 
a review of clinical trials provided by Faught et al. 
of another antiepileptic drug zonisamide (carbon-
ic anhydrase inhibitor), the incidence of clinically 
symptomatic kidney stones increased with long-
term treatment. Among all studies, 15 of 549 pa-
tients (2.7%) had kidney stones (9).
The study by Jhagroo et al. found that urinary ci-
trate excretion declined after starting topiramate 
therapy. Urinary citrate excretion increased after 
adding potassium citrate (10). It supports our re-
sults.
Kidney stones are the metabolic disease which 
usually presents as urologic complications mainly 
as renal colic. The differential diagnosis is broad 
and includes many internal diseases. The systemic 
metabolic acidosis can lead to formation of kidney 
stones. We should consider all potential causes of 
chronic metabolic acidosis.
Metabolic acidosis may develop during progres-
sion of chronic kidney disease (11). The patient had 
estimated glomerular filtration rate (eGFR) always 
over 1.0 ml/s/1.73m2. Patient did not meet the GFR 
criteria for chronic kidney disease. Urine albumin 
to creatinine ratio was repeatedly within reference 
ranges. The patient did not suffer from diabetes 
mellitus. Her serum glucose concentration did not 
meet the criterion for diabetes mellitus. Ketoaci-
dosis or biguanide lactic acidosis induced by this 
disease was not likely. Ethanol induced ketoacido-
sis was not probable. Very low level of patient’s 
gamma-glutamyl transferase did not indicate alco-
hol abuse.
She denied chronic diarrhea. Pancreatic and intes-
tinal diseases with diarrhea lead to loss of bicar-
bonates and metabolic acidosis. Increased absorp-
tion of oxalates in malabsorptive states can lead to 
calcium oxalate stones. Patient had oxaluria within 
reference ranges.
The combination of metabolic acidosis, low urine 
citrate and alkaline urine pH is the typical feature 
of renal tubular acidosis. Hypocitraturia and trend 
to alkaline pH were main features in patient’s 
urine.
Primary hyperparathyroidism causes renal tubular 
disorder, which is a type of acquired renal tubular 
acidosis. This endocrine disease is characterized by 
high serum calcium and parathyroid hormone. It 
causes metabolic acidosis with formation of calci-
um oxalate and calcium phosphate stones (12). El-
evated chloride concentration is typical for hyper-
parathyreosis, but normal patient’s serum calcium 
and parathormon level excluded this diagnosis.
The appropriate treatment of patients with calci-
um kidney stones due to renal tubular acidosis in-
cludes alkalization therapy with potassium citrate. 
The target of treatment is correction of metabolic 
acidosis with extracellular fluid base excess +/- 2 
mmol/L. Gastrointestinal tolerability of citrates is 
the clinical issue. The alkali therapy reduces tubu-
lar reabsorption of citrates, which increases citrate 
excretion. If calcium excretion is over 8 mmol/24 
hours after restoration of acid base balance, treat-
ment with thiazide is also recommended. General 
life style changes are also important. Target life-
style factors include daily fluid intake over 2.5 li-
ters, urine daily volume over 2.5 liters, balanced 
diet rich in vegetables and fibers, limited NaCl and 
animal proteins content in diet, retaining a normal 
BMI level and adequate physical activity (1).
The study is novel in its detailed description of a 
complex set of both blood and urine tests during 
treatment and after it. Possibly the biggest limita-
tion of this study is the fact that it was only per-
formed on a single patient.
We can conclude that we should be aware of topi-
ramate induced metabolic side effects, which in-
clude metabolic acidosis and kidney stones. We 
recommend testing blood acid base balance, uri-
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nary pH and citrates in patients taking topiramate 
and suffering from kidney stones.
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